Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Longeveron Inc (NQ: LGVN ) 1.970 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Longeveron Inc < Previous 1 2 3 4 5 6 7 8 9 ... 11 12 Next > Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved" September 14, 2023 BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions... Via Benzinga Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market September 12, 2023 --News Direct-- Via News Direct Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market September 11, 2023 Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However,... Via Benzinga Upcoming Phase 2 Data Expected For Longeveron’s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer’s Sector – What To Look For September 07, 2023 --News Direct-- Via News Direct Earnings Preview: Longeveron August 10, 2023 Via Benzinga LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates May 12, 2023 LGVN stock earnings show Longeveron reporting a wider loss than analysts expected and missing revenue estimates. Via InvestorPlace Recap: Longeveron Q1 Earnings May 12, 2023 Via Benzinga Preview: Longeveron's Earnings May 11, 2023 Via Benzinga Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For September 06, 2023 Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™... Via Benzinga Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session August 31, 2023 Gainers Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped 145% to $1.4850 after Zevra Therapeutics announced it will acquire the company. The transaction will have a total potential value for Acer... Via Benzinga US Stocks Rise; Initial Jobless Claims Edge Lower August 31, 2023 U.S. stocks traded higher this morning, following the release of economic reports. Following the market opening Thursday, the Dow traded up 0.26% to 34,982.42 while the NASDAQ rose 0.48% to 14,086.54.... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Thursday's Pre-Market Session August 31, 2023 Via Benzinga As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs August 29, 2023 Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. Via Benzinga Earnings Scheduled For August 11, 2023 August 11, 2023 Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million. Via Benzinga Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions August 08, 2023 --News Direct-- Via News Direct Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases August 07, 2023 Wa'el Hashad, CEO of Longeveron (NASDAQ: LGVN), was recently interviewed by Benzinga. Via Benzinga Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions August 07, 2023 Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases. Via Benzinga Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS July 11, 2023 Hypoplastic left heart syndrome, or HLHS, has a historical mortality rate of 20% within five years of diagnosis. The disease affecting children may have a new therapy in Longeveron’s (NASDAQ: LGVN)... Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session July 07, 2023 Via Benzinga HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes? July 07, 2023 HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes? Via News Direct Exposures Product Safety HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron's Lomecel-B Improve Outcomes? June 28, 2023 Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome. Via Benzinga Earnings Scheduled For May 12, 2023 May 12, 2023 Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. Via Benzinga Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free May 09, 2023 Longeveron Inc (NASDAQ: LGVN) announced new long-term follow-up data from its ELPIS I trial of Lomecel-BTM for patients with Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session May 09, 2023 Via Benzinga Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 09, 2023 Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. Via Benzinga Why Is Longeveron (LGVN) Stock Up 30% Today? May 09, 2023 Longeveron (LGVN) stock is on the move Tuesday after releasing new long-term survival data from HLHS treatment Lomecel-B. Via InvestorPlace Longeveron Doses First Patient In Phase 2 Clinical Trial Of Lomecel-B™ In Japan For Aging-Related Frailty April 20, 2023 Longeveron Inc. (NASDAQ: LGVN) announced that the first patient has been treated with Lomecel-BTM in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan. The trial aims to enroll... Via Benzinga Stocks That Hit 52-Week Lows On Tuesday March 21, 2023 On Tuesday, 74 companies achieved new lows for the year. Via Benzinga Earnings Scheduled For March 10, 2023 March 10, 2023 Companies Reporting Before The Bell • CSI Compressco (NASDAQ:CCLP) is estimated to report earnings for its fourth quarter. • Longeveron (NASDAQ:LGVN) is expected to report earnings for its fourth... Via Benzinga Insiders Just Bought $1 Million of This Deep Value Tech Stock March 07, 2023 CEO and CFO buying is a bullish indicator... and based on new SEC filings, things are heating up for IHRT stock. Dive in here. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 ... 11 12 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.